Please login to the form below

Not currently logged in
Email:
Password:

NICE appoints Mark Baker and Alexia Tonnel as directors

Baker becomes director of the centre for clinical practice while Tonnel takes over as director of evidence resources

The UK's National Institute for Health and Clinical Excellence (NICE) has appointed Professor Mark Baker and Alexia Tonnel as directors.

Prof Baker will replace the departing Prof Peter Littlejohns as director of the centre for clinical practice, while Tonnel will take over the role of director of evidence resources following the retirement of Dr Fergus Macbeth.

Both new directors have previously worked for NICE, which evaluates a product's cost-effectiveness and sets clinical guidance in the NHS, for several years.

Prof Baker has been involved with the NICE Guidelines Programme for nearly a decade, has worked as a consultant adviser to the body since 2009, and has chaired two clinical guideline development groups.

His previous experience in healthcare includes serving as chief executive of Bradford Teaching Hospitals and medical director at North Yorkshire health authority, West Yorkshire strategic health authority and Leeds Teaching Hospitals.

Tonnel has been a programme director at NICE since 2010, redesigning and managing the processes for the provision of content into NHS Evidence, the online health information portal NICE runs, and leading the development of new products, including Evidence Updates.

Prior to joining NICE, Tonnel was director at professional services firms Deloitte, advising clients in the life sciences and healthcare industries.

Sir Andrew Dillon, chief executive of NICE, said of the appointments: “Both have a wealth of experience in their respective fields and I am looking forward to working with them.”

8th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics